Key Takeaways December and January will be event-heavy: Based on historical precedent, by late December, Congress and Senate are expected to align on the latest version of the Biosecure Act. This amended version (versus last year's) does not mention the WuXis and provides due process should any company be deemed a "biotech company of concern" in the future (note). Given recent proposed updates to the 1260H list under the Department of Defense (citation), we see passage of the amended, more moderate form of ...